The estimated Net Worth of Gregory Heath is at least $6.52 Миллион dollars as of 17 December 2013. Gregory Heath owns over 1,875 units of Illumina Inc stock worth over $3,493,992 and over the last 17 years Gregory sold ILMN stock worth over $3,022,656.
Gregory has made over 13 trades of the Illumina Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently Gregory exercised 1,875 units of ILMN stock worth $89,644 on 17 December 2013.
The largest trade Gregory's ever made was exercising 209,533 units of Illumina Inc stock on 24 July 2013 worth over $7,593,476. On average, Gregory trades about 14,654 units every 49 days since 2008. As of 17 December 2013 Gregory still owns at least 27,990 units of Illumina Inc stock.
You can see the complete history of Gregory Heath stock trades at the bottom of the page.
Gregory's mailing address filed with the SEC is 9885 TOWNE CENTRE DRIVE, , SAN DIEGO, CA, 92121-1975.
Over the last 22 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley и Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina Inc executives and other stock owners filed with the SEC include: